Programme : Presentations by Room

Platinum Suite 3

Tuesday, 9 October 2018

Tue9  Oct10:50am(10 mins)
Session Chair Introductions Room:
Platinum Suite 3
Tue9  Oct11:30am(15 mins)
Poster Spotlight - Poster 62 - Dr Clio Andreae Room:
Platinum Suite 3
Tue9  Oct12:15pm(5 mins)
Labcyte Inc.
Combining Echo Liquid Handler with high-resolution imaging for exploiting host-directed immunomodulatory therapies PRESENTER - Aurore Lejeune-Dodge ABSTRACT - A promising approach to halt the increase and spread of antimicrobial resistance is to initiate or enhance protective antimicrobial immunity, while limiting inflammation-induced tissue injury. Moreover, immunomodulators targeting the host rather than the pathogen largely avoids selective pressure for the evolution of microbial resistance. In innate immune responses, several types of induced-signaling complexes were structurally determined, commonly referred to as SMOC for Supra-Molecular Organizing Centers[1]. The NEMO protein is the main component of one of these SMOCs called NEMOsome, which is involved in the activation of the NF-kB signaling pathway. Recently characterised using Super Resolution microscopy[2], constituting NEMO is considered a promising target to isolate new immunomodulators in innate immunity. Part of the screening cascade includes a high-resolution image-based assay for the identification of new molecules or drug combinations that enhance the formation of NEMOsome in a stimulus dependent manner, and it has been demonstrated that an Echo Liquid Handler partnered with a specialised type of light microscopy that relies on structured illumination and Synthetic Aperture Optics can increase throughput. A focus screen of FDA-approved library led to the selection of 17 compounds, enhancing the NEMO SMOCs in a IL1 dependent manner, without affecting the basal level of NF-kB activation. These compounds were further validated in a secondary screening using functional NF-kB luminescence gene reporter assay resulting into the confirmation of high nanomolar potency compounds, which increase the NF-kB activation by up to 800-fold without altering basal activity. Other phenotypic screening studies combined with the Echo Liquid Handler are currently in progress to screen other SMOCs such as "MYDDosome", "MAVSome" and "STINGosome", with the aim of identifying new molecules with antimicrobial immunity properties
Room:
Platinum Suite 3
Tue9  Oct12:20pm(5 mins)
Cisbio
HTRF Assays + Reagents for anti-infectives + Rare Diseases Research PRESENTER - Louise Affleck, PhD ABSTRACT - Cisbio has developed easy to use, robust + reliable HTRF assays for anti-infectives + Rare Diseases research. Anti-infectives: e.g. Virus blockade assays using Protein:Protein Interaction reagents Rare Diseases: Frataxin, MBNL1, Survival Motor Neuron (SMN) protein, FMRP and others. Inflammation: assays for IL-1, IL-2, IL-4, IL-6, IL-10, IL-12, IL-18, IL-23, Infn-γ, GCSF, PGE2, Perforin, Granzyme B, TNF-α, TREM-2, pVEGFR and others. Cell-signalling: assays p4EBP1, pSTAT1, pSTAT3, pCREB, pSMAD3, Alpha-Tubulin, pEIF4E, α-SMA, pERK, pAKT, and many, many more…… https://www.cisbio.com/drug-discovery/therapeutic-areas/rare-diseases
Room:
Platinum Suite 3
Tue9  Oct12:25pm(5 mins)
Bio-Rad
Measuring genome editing efficiency using droplet digital PCR PRESENTER - Steve Elliston ABSTRACT - CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and its associated endonuclease Cas9 have emerged as a revolutionary genome engineering tool. Using CRISPR/Cas9 to induce mutations in protein encoding genomic DNA regions is a powerful method for studying protein function in the native cellular context. However, the existing workflows for generating CRISPR/Cas9 knock-out cell lines are cumbersome, labor intensive and comprise of arduous rounds of cloning, limiting dilutions, and surveyor assays performed on dozens if not hundreds of clones. In order for large scale CRISPR/Cas9 studies to become practical and accurate for the genomics community, a streamlined process must be developed and validated at both genomic and protein levels. Here, we report a novel workflow that leverages the power of Droplet Digital PCR (ddPCR) high-resolution melt analysis (HRM), and western blot analysis to generate 3 knock-out cell lines in under 5 weeks.
Room:
Platinum Suite 3
Tue9  Oct02:30pm(15 mins)
Poster Spotlight - Poster 68 - Dr Artur Yakimovich Room:
Platinum Suite 3
Tue9  Oct03:15pm(5 mins)
Horizon Discovery
Horizon’s cellular HTS platform for the identification of beneficial combinations in rare disease PRESENTER - David Sorrell, PhD; HTS Platform Lead ABSTRACT -Horizon is a provider of cellular HTS services and has spent over 15 years industrializing its HTS platform for the rapid identification and prioritization of efficacious monotherapies and combinations across a range of disease indications. Rare diseases are often complex and may require targeting of multiple pathways using drug combinations to achieve clinical responses. Here we provide an overview of Horizon’s HTS platform and exemplify it’s use to identify beneficial combinations in rare disease. Huntington’s disease is an inherited progressive neurodegenerative disorder caused by an expanded CAG repeat tract in the gene encoding for the huntingtin protein (htt). Using a high content image-based assay that measured the localisation of mutant huntingtin we screened combinations of approved drugs and emerging therapeutics and identified synergistic interactions that rescued mutant-specific cellular phenotypes. This demonstrates the power of Horizon’s cellular HTS platform to discover combinations for the potential treatment of rare diseases. Key words: Cellular HTS, combinations, rare disease, Huntington’s disease, high content imaging
Room:
Platinum Suite 3
Tue9  Oct03:20pm(5 mins)
BioIVT
Vaccine Efficacy studies PRESENTER - Amanda J Woodrooffe, PhD ABSTRACT - Vaccines are the most cost-effective medical intervention for viral, bacterial, and parasitic infections, saving millions of lives every year. With a global reach and an ever-expanding scope, vaccines are essential to disease eradication. However, vaccine development is long and expensive, as they are tested for efficacy and safety only in humans. Thus, there is a movement to reduce the time and cost for vaccine development. Once of the key opportunities to accelerate vaccine development is post-approval vaccine efficacy studies, including Phase IV studies. We will discuss BioIVT’s capabilities of supporting and managing post-approval vaccine studies as well as review a case study.
Room:
Platinum Suite 3
Tue9  Oct03:25pm(5 mins)
LGC - ATCC
Room:
Platinum Suite 3
Multi-targeting to reduce bacteria resistance
Tue9  Oct04:00pm(30 mins)
Prof Chris Dowson Prof Chris Dowson  
Room: Platinum Suite 3

Wednesday, 10 October 2018

Wed10  Oct10:40am(10 mins)
Drug Discovery Networks- Alliances, Partnerships, CRO Relationships and Open Innovation - Session Chair Introductions Room:
Platinum Suite 3
Wed10  Oct11:20am(5 mins)
LifeArc
PRESENTER - Roberto Zanchi, Business Development Manager ABSTRACT - LifeArc, formerly MRC Technology, is a medical research charity with over 25 years’ experience in working with academics, charities and industry to bridge the gap between basic research and early drug discovery. A number of mechanisms for achieving this have been tried and tested. One of these is through collaboration with our Centre for Therapeutics Discovery (CTD), where there are over 90 scientists supporting early stage target validation, hit identification and lead optimisation for both small molecule and antibody projects. This presentation will give an overview of how we can help academic scientists to translate their research closer to the clinic, and of the new ways that LifeArc is using to support the translation of “great science into greater patient impact”.
Room:
Platinum Suite 3
Wed10  Oct11:25am(5 mins)
NMI TT Pharmaservices
Genome editing in customized cell lines. PRESENTER - Richard Griesbach. ABSTRACT - NMI TT Pharmaservices offers pre-clinical testing of lead compounds, immunotherapies and combo treatments using patient-derived 3D microtumours of various tumour entities, in co-culture with autologous immune cells. Our fee-for-service offerings also include generation of custom stable cell lines, CRISPR genome editing, hiPSC technology, and a broad range of protein profiling technologies (DigiWest, RPPA, Luminex, Simoa, etc.). For details, please meet us at booth C2, or visit our website: www.nmi-tt.de/pharmaservices
Room:
Platinum Suite 3
Wed10  Oct12:00pm(15 mins)
Poster Spotlight - Poster 5 - Dr Catherine Goh Room:
Platinum Suite 3
Wed10  Oct12:15pm(5 mins)
REPROCELL
Human tissue models to improve the prediction of clinical efficacy PRESENTER - Dr. David Bunton ABSTRACT - Human disease-relevant tissue is increasingly viewed as an approach to reduce clinical failure rates, particularly during phase II and III trials, where poor efficacy has been partly attributed to an over-reliance on animal models. Fresh human tissue assays and complex tissues grown in 3D aim to bridge the knowledge gap between simple 2D cell-based studies, in vivo animal studies and clinical trials. Human fresh tissues and 3D models offer advantages over simpler cell-based models, avoid species differences and, when sourced from patients or grown from patient-derived material, they can truly reflect the diverse patient population. The decline of the blockbuster drug and move towards precision medicine necessitates the use of human data, to better understand the variation that exists within target patient populations. By combining functional assays in human tissues with genomics, a truly pharmacogenomic approach to drug discovery can be embraced at early stages of development. The presentation will review the range of human tissue-based approaches available at REPROCELL’s Centre for Predictive Drug Discovery and their potential within precision medicine.
Room:
Platinum Suite 3
Wed10  Oct12:20pm(5 mins)
Merck
Enhanced Antibody Validation at Merck PRESENTER - Hardeep Grewal ABSTRACT - Many concerned scientists have called for more rigorous evidence that commercial antibodies specifically bind the intended target. The International Working Group for Antibody Validation (IWGAV) has recommended best approaches for validating antibodies used in common research applications, and has published suggested guidelines that are intended to enhance antibody reproducibility. The IWGAV has suggested ‘pillars’ for validation of antibodies that would enhance confidence in their function in biomedical and immunodetection applications. In answer to calls for more stringent corroboration of immunodetection application-based antibody validation, we are pleased to offer, enhanced validation for many antibodies in our portfolio. Enhanced validation (EV) data that are now represented on our product pages align with several of the 2016 IWGAV guidelines for more rigorous specificity testing, and are available for those antibodies in our catalogue that carry the EV symbol. As a leading provider of primary antibody products that are validated every day by your peers through the immense number of peer reviewed citations of the use of our antibodies. Industry leading quality control processes and application testing ensure that you can rely on our antibodies to provide the expected performance the first time and every time. In addition to our long-standing commitment to validation, we continue to expand and improve our processes by incorporating more rigorous validation strategies into the development of many of our antibody reagents.
Room:
Platinum Suite 3
Wed10  Oct12:25pm(5 mins)
FUJIFILM Cellular Dynamics
Genome engineering strategies in iPSC lines offer isogenic controls in disease modelling: a case of Hypertrophic Cardiomyopathy "in-a-dish" PRESENTER - Giorgia Salvagiotto - Senior Field Application Scientist ABSTRACT - Sarcomeric cardiomyopathies, including hypertrophic cardiomyopathy (HCM), are an important cause of morbidity and mortality. Clinically, HCM is characterized by ventricular wall thickening as a result of enlarged cardiomyocytes, preserved ejection fraction concurrent with diastolic dysfunction, and arrhythmias. One of the most common forms of HCM arises from a missense mutation in the gene encoding the beta myosin heavy chain protein (MYH7), resulting in a change of amino acid 403 from arginine-to-glycine (R403Q). However, the pathobiology of this mutation remains generally poorly understood. A major hindrance to detailed study of sarcomeric cardiomyopathies in humans has been lack of an appropriate in vitro cardiac tissue model. Here, we use human induced pluripotent stem cell derived-cardiomyocytes (hiPSC-CMs) to study the functional consequence of the HCM MYH7 R403Q mutation, specifically electrophysiology, calcium handling, and contraction. HiPSC-CMs were generated through reprogramming of somatic cells from a patient carrying the HCM MYH7 R403Q mutation. In addition, we use genome engineering strategies to correct the mutation, creating an isogenic control. The inherited cardiomyopathy model displays classic hallmarks of hypertrophy, including up-regulation of fetal genes, cytoskeletal rearrangements, and increased hiPSC-CM size. In addition, the HCM MYH7 R403Q hiPSC-CMs display abnormal electrophysiological properties and calcium handling properties including significantly slower calcium decay rates and prolonged calcium handling kinetics concurrent with contractile dysfunction. These data illustrate the advantages of disease modeling using hiPSC technology. We conclude that patient-specific hiPSC-CMs exhibit classic clinical phenotypes relative to control.
Room:
Platinum Suite 3
Wed10  Oct03:00pm(15 mins)
Poster Spotlight - Poster 56 - Steven van Helden Room:
Platinum Suite 3

Hosted By

ELRIG
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2021